StockData

biote vs Niagen Bioscience

BTMD and NAGE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BTMD and NAGE compare

Niagen Bioscience is the larger company, worth 4.6 times as much as biote ($159M against $34.5M).

On earnings, biote is cheaper: it trades at 9.6× trailing earnings, against 16.8× for Niagen Bioscience.

Niagen Bioscience grew revenue faster over the last twelve months (−1.9% versus −7.8% for biote).

Niagen Bioscience keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with 3.2% at biote.

Niagen Bioscience scores higher on the StockData Score (14 against 8 for biote), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBTMDNAGE
Size and price
Market cap$34.5M$159M
Share price$0.960$2.01
Change, 1 year−63.1%−71.2%
Change, 5 years−90.1%−59.1%
Beta (5Y)2.001.08
Employees223117
StockData Score
Total score814 (better)
Valuation score4 (better)3
Growth score01 (better)
Performance score24 (better)
Health score26 (better)
Dividend score00
Valuation
P/E9.6× (better)16.8×
P/S0.2× (better)1.3×
P/B–1.9×
EV/EBITDA8.2× (better)18.8×
P/FCF1.7×–
FCF yield57.6%–
Fair value$3.21$2.30
Margin of safety70.1% (better)12.6%
Growth
Revenue growth (TTM)−7.8%−1.9% (better)
Revenue growth, 5Y average–16.9%
Net income growth (TTM)−81.3%−49.9% (better)
EPS growth (TTM)−88.9%−50.0% (better)
Profitability
Gross margin68.6% (better)63.9%
Operating margin8.0% (better)3.9%
Net margin3.2%8.4% (better)
FCF margin10.8%–
Return on equity–13.3%
Return on invested capital45.7% (better)44.3%
Financial health
Debt / equity–0.00
Net debt / EBITDA5.93–
Current ratio1.435.93 (better)
Altman Z-score1.863.87 (better)
Piotroski F-score67 (better)
Dividends and buybacks
Payout ratio19.9%–
Buyback yield–3.4%
Shareholder yield0.00%3.4% (better)
Ownership
Held by institutions36.6%40.4%
Held by insiders23.3%5.1%
Insider net buying, 12 months$202K (better)$0
Short interest, % of float3.1%5.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.